Zusammenfassung
Im Rahmen eigener experimentellen Untersuchungen in vitro gelang es nachzuweisen,
dass IL-8 von humanen Melanomzellen sezerniert wird. Die Blockade der IL-8-Freisetzung
mittels neutralisierender Antikörper oder alternativ molekularbiologisch durch Zugabe
von IL-8-Sequenz-spezifischen Antisense-Oligonukleotiden belegten die Bedeutung von
IL-8 als potenter Wachstumsfaktor für Melanomzellen, der sowohl parakrin als auch
autokrin wirken kann. In-situ-Hybridiserungen an Primärtumoren und benignen melanozytären
Kontrollen wiesen auf eine gewisse prognostische Relevanz des IL-8-Nachweises beim
Melanom hin. Im Nacktmausmodell war durch andere Gruppen eine klare Assoziation mit
Wachstumsdynamik und Metastasierung nachweisbar, die in neusten Untersuchungen mit
einem humanisierten, IL-8-neutralisierenden Antikörper therapeutisch günstigt beeinflusst
werden konnte. Es bleibt abzuwarten, ob dieser Erfolg versprechende Antikörper in
naher Zukunft erste klinische Studien erreicht.
Abstract
In a series of in-vitro experiments our group demonstrated that human melanoma cells
secrete soluble IL-8. Blockade of IL-8 secretion either by neutralizing antibodies
or by molecular biological techniques such as antisense oligomers led to a pronounced
growth inhibition of melanoma cells and confirm the role of IL-8 as a paracrine and/or
autocrine growth factor. Further in-situ hybridisation on primary melanomas as well
as benign melanocytic nevi revealed a correlation between IL-8 expression and cinical
parameters such as time-to-progression. Additional work by other groups confirmed
a strong association between IL-8 and tumor growth and metastasis in a nude mouse
model. In the same model a fully humanized IL-8 neutralizing antibody was able to
significantly alter the clinical outcome. It remains to be seen whether these promising
antibodies will find their way into the clinic in the near future.
Literatur
- 1
Schadendorf D.
Is there a standard for the palliative treatment of melanoma?.
Onkologie.
2002;
25
74-76
- 2
Schadendorf D, Möller A, Algermissen B, Worm M, Sticherling M, Czarnetzki B M.
IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine
growth factor.
J Immunol.
1993;
151
2667-2675
- 3
Schröder J M, Mrowietz U, Morita E, Christophers E.
Purification and partial biochemical characterization of a human moncyte-derived neutrophil-activating
peptide that lacks interleukin-1 activity.
J Immunol.
1987;
139
3474-3483
- 4
Scheibenbogen C, Mohler T, Haefele J, Hunstein W, Keilholz U.
Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates
with tumour load.
Melanoma Res.
1995;
5
179-181
- 5
Nürnberg W, Tobias D, Otto F, Henz B M, Schadendorf D.
Expression of interleukin-8 detected by in situ hybridization correlates with worse
prognosis in primary cutaneous melanoma.
J Pathol.
1999;
189
546-551
- 6
Singh R K, Gutman M, Radinsky R, Bucana C D, Fidler I J.
Expression of interleukin 8 correlates with the metastatic potential of human melanoma
cells in nude mice.
Cancer Res.
1994;
54
3242-3247
- 7
Varney M L, Li A, Dave B J, Bucana C D, Johansson S L, Singh R K.
Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic
potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic
phenotype.
Clin Exp Metastasis.
2003;
20
723-731
- 8
Lev D C, Ruiz M, Mills L, McGary E C, Price J E, Bar-Eli M.
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial
growth factor in melanoma cells: a possible escape mechanism from chemotherapy.
Mol Cancer Ther.
2003;
2
753-763
- 9
Lev D C, Onn A, Melinkova V O, Miller C, Stone V, Ruiz M, McGary E C, Ananthaswamy H N,
Price J E, Bar-Eli M.
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis
in vivo.
J Clin Oncol.
2004;
22
2092-2100
- 10
Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang X D, Gudas J M, Bar-Eli M.
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis,
tumor growth, and metatstasis of human melanoma.
Am J Pathol.
2002;
161
125-134
- 11
Ugurel S, Rappl G, Tilgen W, Reinhold U.
Increased serum concentration of angiogenic factors in malignant melanoma patients
correlates with tumor progression and survival.
J Clin Oncol.
2001;
19
577-583
Prof. Dr. Dirk Schadendorf
Klinische Kooperationseinheit für Dermatoonkologie (DKFZ) an der Klinik für Dermatologie,
Venerologie und Allergologie Universitätsklinikum Mannheim
Theodor Kutzer Ufer ·
68135 Mannheim
Email: d.schadendorft@dkfz.de